KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Prognostic and predictive analyses of circulating plasma biomarkers in men with metastatic castration resistant prostate cancer treated with docetaxel/prednisone with or without bevacizumab.Prostate Cancer Prostatic DisPMID 38347114PMC113175412025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double-dummy pilot trial.HeadachePMID 39290050PMC121292452025-Jun0.98未发现恶性肿瘤人群证据。待处理
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.Int J Gynecol Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39322611无 PMCID2025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP: Randomised phase 3 study.J Sleep ResPMID 39377364PMC120697292025-Jun0.98未发现恶性肿瘤人群证据。待处理
Treatment of early-onset fetal growth restriction with low molecular weight heparin does not prolong gestation: a randomized clinical trial.Am J Obstet GynecolPMID 39521297无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216.Eur Urol OncolPMID 39521639PMC120591432025-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial.Eur UrolPMID 39537438无 PMCID2025-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Resolution of Angiographic Macular Leakage with Faricimab versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE.Ophthalmol RetinaPMID 39580145无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial.Arthritis RheumatolPMID 39609094PMC121232552025-Jun0.98未发现恶性肿瘤人群证据。待处理
Maribavir for refractory cytomegalovirus infection (with or without resistance) in solid organ transplant recipients: Subgroup analysis of the phase 3 randomized SOLSTICE study.J Heart Lung TransplantPMID 39613120无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Treatment With Oral or Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension and Cardiovascular Comorbidities.ChestPMID 39622469无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Association Between age or Duration of Diagnosis in Obstructive Hypertrophic Cardiomyopathy and Response to Mavacamten Treatment: Exploratory Analysis of the EXPLORER-HCM Trial.J Card FailPMID 39653325无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer.Clin Colorectal Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39743478无 PMCID2025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.Clin ObesPMID 39800653PMC120960582025-Jun0.98未发现恶性肿瘤人群证据。待处理
Impact of Treatment With Trifluridine/Tipiracil in Combination With Bevacizumab on Health-Related Quality of Life and Performance Status in Refractory Metastatic Colorectal Cancer: An Analysis of the Phase III SUNLIGHT Trial.Clin Colorectal Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39818468无 PMCID2025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials.Eur J Heart FailPMID 39844714PMC122603342025-Jun0.98未发现恶性肿瘤人群证据。待处理
Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial.Eur Urol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 39884884无 PMCID2025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Concomitant Use of Etrasimod With Opioids or Antidepressants in Patients With Ulcerative Colitis-A Safety Analysis.United European Gastroenterol JPMID 39891572PMC121883542025-Jun0.98未发现恶性肿瘤人群证据。待处理
Evaluating mediators of the effect of varenicline preloading on smoking abstinence in a randomized controlled trial.AddictionPMID 39915904PMC122122352025-Jun0.98未发现恶性肿瘤人群证据。待处理
Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial.Clin Microbiol InfectPMID 39922466PMC120689742025-Jun0.98未发现恶性肿瘤人群证据。待处理
Pharmaco-invasive strategy and dosing of tenecteplase in STEMI patients 60 to <75 years: An inter-trial comparison of the STREAM-1 and STREAM-2 trials.Am Heart JPMID 39952376无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme.J Eur Acad Dermatol VenereolPMID 39962358PMC121054262025-Jun0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of elobixibat in patients with chronic constipation-A randomized, multicenter, double-blind, placebo-controlled, parallel-group study from India.Indian J GastroenterolPMID 39985701PMC121411652025-Jun0.98未发现恶性肿瘤人群证据。待处理
A phase III study comparing preservative-free latanoprost eye drop emulsion with preserved latanoprost in open-angle glaucoma or ocular hypertension.Eye (Lond)PMID 40000909PMC120895862025-Jun0.98未发现恶性肿瘤人群证据。待处理
Acute subanesthetic ketamine-induced effects on the mismatch negativity and their relationship to early and sustained treatment response in major depressive disorder.J PsychopharmacolPMID 40012166PMC122051652025-Jun0.98未发现恶性肿瘤人群证据。待处理
Harms of Morphine for Chronic Breathlessness in Relation to Dose, Duration and Titration Phase.J Pain Symptom ManagePMID 40015533无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Comparison of Complication and Readmission Rates Between Robot-Assisted and Open Radical Cystectomy: Results From the Randomized RAZOR Clinical Trial.J UrolPMID 40080805PMC120643582025-Jun0.93干预为非药物单独策略,未满足药物干预要求。待处理
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF.JACC Heart FailPMID 40088233无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Early toxicity of moderately hypofractionated radiation therapy in breast cancer patients receiving locoregional irradiation: First results of the UNICANCER HypoG-01 phase III trial.Radiother OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40097073无 PMCID2025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.Nat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PMC Figure,均未识别为 KM 图:Fig. 1:研究设计图;Fig. 2:非 KM 图;Fig. 3:非 KM 图;Fig. 4:森林图/亚组分析图;Fig. 5:森林图/亚组分析图;另有 2 张未列出。PMID 40097663PMC121766152025-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。无 KM 图
Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration-Resistant Prostate Cancer: PROpel Subset Analysis.Cancer SciPMID 40099663PMC121271122025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。已完成
The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials.J Am Geriatr SocPMID 40105285PMC122052982025-Jun0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV-1 initiating first-line therapy: 5-year follow-up from two phase III studies.HIV MedPMID 40116337PMC121272362025-Jun0.98未发现恶性肿瘤人群证据。待处理
Clinicopathological Factors Affecting Stomach Preservation Following Laparoscopic Sentinel Node Navigation Surgery in Patients with Early Gastric Cancer: A Secondary Analysis of the Multicenter Randomized Phase III SENORITA Trial.Ann Surg OncolPMID 40117015无 PMCID2025-Jun0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
A Phase III Randomized, Double-Blind, Active-Controlled, Multicenter Study on the Efficacy and Safety of Ezetimibe/Atorvastatin/Amlodipine Combination in Patients With Comorbid Primary Hypercholesterolemia and Essential Hypertension.Clin TherPMID 40122716无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Impact of adding palbociclib on treatment adherence to ongoing adjuvant endocrine treatment in the global randomized PALLAS randomized trial in patients with early breast cancer.Breast Cancer Res TreatPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。PMID 40140172无 PMCID2025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Immunogenicity of adjuvanted recombinant SARS-CoV-2 spike protein vaccine after earlier mRNA vaccine doses.J Allergy Clin ImmunolPMID 40154575无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.J Clin Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图;FIG 4.:森林图/亚组分析图;FIG 5.:非 KM 图。PMID 40179324PMC121186242025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Does the Burden of CSVD Modify the Efficacy of Dual Antiplatelet Therapy?: A Post Hoc Analysis of the INSPIRES Trial.StrokePMID 40190261无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Estimating the Impact of Adjuvant Treatment With Nivolumab on Long-Term Survivorship Rates Compared With Surveillance in Muscle Invasive Urothelial Carcinoma: Mixture Cure Modeling Analyses of Disease-Free Survival From the Phase 3 CheckMate 274 Trial.Clin Genitourin Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40204616无 PMCID2025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial.Nat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40217078无 PMCID2025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图
ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia Gravis.Ann Clin Transl NeurolPMID 40223516PMC121721142025-Jun0.98未发现恶性肿瘤人群证据。待处理
Mepitel Film Versus StrataXRT in Managing Radiation Dermatitis in an Intra-Patient Controlled Clinical Trial of 80 Postmastectomy Patients.J Med Imaging Radiat OncolPMID 40223795PMC121752152025-Jun0.95The study is an oncology (breast cancer), human, randomized, Phase III trial reporting original results. However, it is ineligible because: 1) The primary endpoint is moist desquamation rate (a binary incidence outcome at a fixed time), not a time-to-event efficacy endpoint requiring Kaplan-Meier analysis or hazard ratios. 2) The interventions are Mepitel film and StrataXRT, which are medical devices/topical products, not drug-containing interventions.待处理
Efficacy and safety of intravenous vedolizumab treatment in Chinese patients with moderate-to-severe Crohn's disease.Clin Res Hepatol GastroenterolPMID 40228712无 PMCID2025-Jun0.80The study is a randomized, double-blind, placebo-controlled Phase 3 trial of vedolizumab for Crohn's disease, which is not a malignant neoplasm. While it meets criteria for human, randomized, Phase 3, drug intervention, and original results, it is not an oncology study. Furthermore, the primary and secondary endpoints are clinical response and remission scores, not time-to-event outcomes. Therefore, it is ineligible.待处理
Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS.Mult SclerPMID 40237070PMC121593532025-Jun0.98未发现恶性肿瘤人群证据。待处理
Patient-reported outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib: results from the PhALLCON trial.LeukemiaPMID 40240572PMC121335732025-Jun0.95While the parent trial is an eligible oncology Phase III randomized drug trial, this specific report is a secondary analysis focused on patient-reported outcomes and quality of life, which are excluded per adjudication rules. The required primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS) is not the subject of this report.待处理
Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial.Lancet Respir MedPMID 40245915无 PMCID2025-Jun0.98未发现恶性肿瘤人群证据。待处理
Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA).Drugs R DPMID 40279006PMC121858222025-Jun0.98未发现恶性肿瘤人群证据。待处理
TFOX versus FOLFOX in first-line treatment of patients with advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (PRODIGE 51- FFCD-GASTFOX): an open-label, multicentre, randomised, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40286809无 PMCID2025-Jun1.00命中用户提供的消化道肿瘤阳性参考集。无 KM 图
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。PMID 40300278无 PMCID2025-Jun0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。无 KM 图